U.S. Markets open in 8 hrs 51 mins

CLASS ACTION UPDATE for CBL, HRTX and CLDR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / July 12, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the lead plaintiff deadlines listed below to petition the court, and those interested in their eligibility are encouraged to contact the firm. There will be no cost or obligation to you.

CBL & Associates Properties, Inc (CBL)

Lawsuit on behalf of: investors who purchased July 29, 2014 - March 26, 2019
Lead Plaintiff Deadline : July 16, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cbl-associates-properties-inc-loss-form?prid=2367&wire=1.

According to the filed complaint, during the class period, CBL & Associates Properties, Inc made materially false and/or misleading statements and/or failed to disclose that: the Company was the target of a class action suit that could result in tens of millions or even hundreds of millions of dollars in liability. The Complaint further alleges that Defendants completely ignored their disclosure obligation, motivated by a desire to avoid bad publicity surrounding their dishonest nature and their dishonest conduct. When the truth was revealed, CBL shares materially declined in price, injuring the class.

Heron Therapeutics, Inc. (HRTX)

Lawsuit on behalf of: investors who purchased October 31, 2018 - April 30, 2019
Lead Plaintiff Deadline : August 5, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/heron-therapeutics-inc-loss-form?prid=2367&wire=1.

According to the filed complaint, during the class period, Heron Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Heron had failed to include adequate Chemistry, Manufacturing, and Controls (“CMC”) and non-clinical information in its NDA for HTX-011; (ii) the foregoing increased the likelihood that the FDA would not approve Heron’s NDA for HTX-011; and (iii) as a result, Heron’s public statements were materially false and misleading at all relevant times.

Cloudera, Inc. (CLDR)

Lawsuit on behalf of: investors who purchased April 28, 2017 - June 5, 2019
Lead Plaintiff Deadline : August 6, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cloudera-inc-loss-form?prid=2367&wire=1.

According to the filed complaint, during the class period, Cloudera, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Cloudera was finding it increasingly difficult to identify large enterprises interested in adopting the Company’s Hadoop-based platform; (ii) Cloudera needed to expend an increasing amount of capital on sales and marketing activities to generate new revenues, even as new revenue opportunities were diminishing; and (iii) Cloudera had materially diminished sales opportunities and prospects and could not generate annual positive cash flows.

You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/551785/CLASS-ACTION-UPDATE-for-CBL-HRTX-and-CLDR-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders